摘要
目的:探讨新辅助化疗对中晚期卵巢癌患者复发和预后的影响。方法:回顾性分析52例中晚期卵巢癌患者的治疗及预后,32例术前采用全身序贯化疗(standard sequence chemotherapy SSC)+腹腔内灌注化疗2个疗程。术后用DNA原位末端标记检测肿瘤细胞凋亡并随访观察癌复发和生存时间。结果:新辅助化疗组与未术前化疗组肿瘤细胞凋亡数分别为(50.71;3.87)和(29.13;3.69)个?高倍视野,观察组1、3、5年复发率为12.5%(4/32)、25%(8/32)、59.4%(19/32);生存率100%(32/32)、78.1%(25/32)、22%(7/32)。对照组1、3、5年复发率35%(7/20)、45%(9/20)、90%(18/20);生存率80%(16/20)、55%(11/20)、20%(4/20)。3年生存率的比较中,化疗组为25例,明显高于无术前化疗组11例,P<0.05,差异有显著意义。而5年生存率差,P>0.05异则无显著意义。术前化疗组中,腹痛腹胀等症状缓解率为30%,肿块缩小率(PR+CR)为62.5%,基本切净率为93%。残留>2cm有2例。无术前化疗组中,基本切净率为85%,残留>2cm有3例,相比,P<0.05,差异有显著意义。结论:新辅助化疗对卵巢癌细胞有明显促凋亡作用,是预防癌复发转移和改善预后的有效手段。
Objective：The effect of recurrence and prognosis of advanced ovarian carcinoma treated by the new assistant chemotherapy.Methods：The 32 presurgical cases received SSC and celiac chemotherapy,DDP,CTX were infused.The death of tumor cell were tested by DNA terminal method;recurrence and prognosis were analyzed.The other 20 cases,treated by radical resection directly.Results：The 1,3,5-year survival rates in treatment group were 100%,78.1%,22% respectively while in the controe other group were 80%,55%,20%.The difference between the 2 groups was statistically significant（P〈0.05）.Conclusion：the new assistant chemotherapy was an effective treatment for ovarian carcinoma.
出处
《现代肿瘤医学》
CAS
2007年第10期1489-1490,共2页
Journal of Modern Oncology
关键词
卵巢肿瘤
新辅助化疗
凋亡
预后
ovarian carcinoma
assistant chemotherapy
recurrence
prognosis
